Society guideline links: Cannabis use disorder and withdrawal

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately.

●(See "Society guideline links: Opioid use disorder and withdrawal".)

●(See "Society guideline links: Alcohol use disorders and withdrawal".)

●(See "Society guideline links: Stimulant use disorder and withdrawal".)

●(See "Society guideline links: Benzodiazepine use disorder and withdrawal".)

International

●World Health Organization (WHO): Guidelines for the identification and management of substance use and substance use disorders in pregnancy (2014)

Canada

●Canadian Network for Mood and Anxiety Treatments (CANMAT): Systematic review and recommendations of cannabis use in bipolar disorder and major depressive disorder – Task force report (2022)

●Canadian Coalition for Seniors' Mental Health (CCSMH): Canadian guidelines on cannabis use disorder among older adults (2020)

●CANMAT: Recommendations for the management of patients with mood disorders and comorbid substance use disorders (2012)

United States

●US Department of Veterans Affairs (VA)/Department of Defense (DoD): Clinical practice guidelines for the management of substance use disorder (SUD) (2021)

●American Heart Association (AHA): Scientific statement on medical marijuana, recreational cannabis, and cardiovascular health (2020)

●US Preventive Services Task Force (USPSTF): Final recommendation statement on unhealthy drug use – Screening (2020)

●American College of Physicians (ACP): Position paper on health and public policy to facilitate effective prevention and treatment of substance use disorders involving illicit and prescription drugs (2017)

●Federation of State Medical Boards (FSMB): Model guidelines for the recommendation of marijuana in patient care (2016)

●Substance Abuse and Mental Health Services Administration (SAMHSA): A Treatment Improvement Protocol (TIP) for detoxification and substance abuse treatment (2006, revised 2015)

●SAMHSA: A Treatment Improvement Protocol (TIP) for managing depressive symptoms in substance abuse clients during early recovery (2008, revised 2014)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Quality standard on drug misuse prevention (2018)

●NICE: Guideline for drug misuse prevention − Targeted interventions (2017)

●NICE: Guideline on controlled drugs − Safe use and management (2016)

●British Association for Psychopharmacology (BAP): Updated evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity – Recommendations (2012)

●NICE: Quality standard on drug use disorders in adults (2012)

●NICE: Clinical guideline on coexisting severe mental illness (psychosis) and substance misuse − Assessment and management in healthcare settings (2011)